January 8, 2014

News stories about doctor shopping and prescription pad pilfering in pursuit of a pain-pill induced high have become commonplace, prompting many legislators and regulators to consider further restrictions on pain medicines like hydrocodone compounds. But there may be a story that’s not being told — that the patients who suffer from chronic pain and need that hydrocodone to reclaim their lives are being stigmatized. The prevalence of pain pill abuse has left in its wake as many as 116 million legitimate pain sufferers who are finding it more difficult to access their therapies.

July 29, 2015

The Consumer Healthcare Products Association expressed support for the DXM Abuse Prevention Act, introduced into the U.S. House of Representatives by U.S. Reps. Bill Johnson, R-Ohio, and Doris Matsui, D-Calif., on Wednesday.

June 10, 2015

Despite high-profile efforts to implement abuse-deterrent labels and properties on brand-name opioids, advisory company Avalere Health’s latest research notes a key blind spot in the efforts — accessibility.

May 19, 2015

Pharmacy Quality Alliance has endorsed three new performance measures to assess the use of opioids. 

April 10, 2015

Tennessee on Wednesday became the eighth state to restrict DXM sales. 

March 31, 2015

The drug is Food and Drug Administration-approved to treat opioid-induced constipation in adults with chronic, non-cancer pain. 

March 11, 2015

Mylan expanded its portfolio of generic products with the U.S. launch of buprenorphine hydrochloride sublingual tablets in 2-mg and 8-mg strengths, the generic version of Subutex from Reckitt Benckiser.

February 27, 2015

Epic Pharma on Friday launched two generics: a schedule II pain reliever and a calcium channel blocker. 

February 25, 2015

In 10 years, the percentage of opioid analgesic users who used an opioid analgesic stronger than morphine increased from 17% to 37%, NCHS reported Wednesday. 

February 20, 2015

Actavis on Friday gained approval for a generic version of Reckitt Benckiser's Subutex, indicated for the treatment of opioid dependence.

February 3, 2015

Zogenix last week announced that the Food and Drug Administration approved a new formulation of the company's Zohydro ER (hydrocodone bitartrate) extended-release capsules, CII.

January 26, 2015

Purdue Pharma on Monday announced the launch of Hysingla ER (hydrocodone bitartrate) extended-release tablets CII. According to the company, the once-daily drug is the first and only hydocodone product to be recognized by the Food and Drug Administration as having properties that deter misuse and abuse via chewing, snorting and injection.

January 14, 2015

Egalet Corp. last week announced the licensing and acquisition of two pain products. Egalet has agreed to license worldwide rights to Oxaydo (oxycodone HCI, USP) tablets for oral use only -CII, the first and only approved immediate-release oxycodone product formulated to deter abuse via snorting from Acura Pharmaceuticals, the company stated.

December 16, 2014

Use of cigarettes, alcohol and abuse of prescription pain relievers among teens has declined since 2013, while marijuana use rates were stable, according to the 2014 Monitoring the Future survey, released Tuesday.

December 9, 2014

From 2009 to 2013, the number of Americans using prescription opiates declined 9.2%, yet both the number of opioid prescriptions filled and the number of days of medication per prescription rose more than 8% in that time period. 

December 2, 2014

Teva Pharmaceuticals on Monday announced the introduction and availability of Buprenorphine Hydrochloride and Naloxone Hydrochloride Dihydrate Sublingual Tablets, CIII.

November 20, 2014

Purdue Pharma on Thursday announced that the Food and Drug Administration approved Hysingla ER (hydrocodone bitartrate) extended‐release tablets CII, a once‐daily, single‐entity medication formulated using Purdue’s proprietary extended‐release solid oral platform, Resistec.

October 22, 2014

Pfizer last week announced that the Food and Drug Administration approved a revised label for Embeda (morphine sulfate and naltrexone hydrochloride) extended-release capsules, for oral use, CII, to include abuse-deterrence studies. 

 

October 17, 2014

Purdue Pharma has launched an awareness campaign to address specific knowledge gaps among pharmacists related to its Schedule III extended-release transdermal opioid, Butrans.

October 10, 2014

The Drug Enforcement Administration’s final rule moving hydrocodone combination products from Schedule III to the more-restrictive Schedule II officially went into effect on Monday. 

October 9, 2014

Purdue Pharma on Thursday announced the launch of a new dosage strength of 7.5 mcg/hour for its Butrans (buprenorphine) transdermal system CIII, bringing the total number of strengths offered by the company to five.

October 8, 2014

Teva Pharmaceutical Industries on Wednesday announced the initiation of a rolling new drug application submission for hydrocodone bitartrate extended-release tablets.

September 30, 2014

Salix Pharmaceuticals and Progenics Pharmaceuticals announced that the Food and Drug Administration approved Relistor (methylnaltrexone bromide) subcutaneous injection in 12-mg dosage strength to treat constipation in patients taking opioids for chronic, non-cancer pain. 

September 26, 2014

Actavis on Friday confirmed that it has filed an abbreviated new drug application with the Food and Drug Administration to market buprenorphine transdermal system, a generic version of Butrans from Purdue Pharma.